Correction to: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies (Rheumatology and Therapy, (2024), 11, 5, (1363-1382), 10.1007/s40744-024-00708-8)
Mease PJ., Merola JF., Tanaka Y., Gossec L., McInnes IB., Ritchlin CT., Landewé RBM., Asahina A., Ink B., Heinrichs A., Bajracharya R., Shende V., Coarse J., Coates LC.
In this article, the Disease Activity Index for Psoriatic Arthritis (DAPSA) disease states were calculated incorrectly, resulting in patients being wrongly allocated to a worse DAPSA disease state. This error impacted two rows in Table 2. The incorrect version and the corrected rows from Table 2 are provided below. The original article has been corrected. Additional efficacy outcomes (week 104/100) and patient reported outcomes (week 104/88) BE OPTIMAL (bDMARD-naïve) BE COMPLETE (TNFi-IR) PBO → BKZ 160 mg Q4W n = 281 BKZ 160 mg Q4W n = 431 ADA → BKZ 160 mg Q4Wa n = 140 PBO → BKZ 160 mg Q4W n = 133 BKZ 160 mg Q4W n = 267 NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) DAPSAc LDA + REM 141 (50.2) 141/226 (62.4) 228 (52.9) 228/349 (65.3) 77 (55.0) 77/107 (72.0) 71 (53.4) 71/101 (70.3) 123 (46.1) 123/204 (60.3) REM 56 (19.9) 56/226 (24.8) 102 (23.7) 102/349 (29.2) 39 (27.9) 39/107 (36.4) 22 (16.5) 22/101 (21.8) 42 (15.7) 42/204 (20.6) Additional efficacy outcomes (week 104/100) and patient reported outcomes (week 104/88) BE OPTIMAL (bDMARD-naïve) BE COMPLETE (TNFi-IR) PBO → BKZ 160 mg Q4W n = 281 BKZ 160 mg Q4W n = 431 ADA → BKZ 160 mg Q4Wa n = 140 PBO → BKZ 160 mg Q4W n = 133 BKZ 160 mg Q4W n = 267 NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) NRI n (%) OC n/N (%) DAPSAc LDA + REM 167 (59.4) 167/226 (73.9) 265 (61.5) 265/349 (75.9) 82 (58.6) 82/107 (76.6) 83 (62.4) 83/101 (82.2) 156 (56.6) 151/204 (74.0) REM 85 (30.2) 85/226 (37.6) 158 (36.7) 158/349 (45.3) 52 (37.1) 52/107 (48.6) 35 (26.3) 35/101 (34.7) 79 (29.6) 79/204 (38.7)